This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Nevro Corp. Announces Publication Of Positive Six-Month Clinical Data For Senza® HF10™ High-Frequency Spinal Cord Stimulation Therapy In Europe

The Senza system delivers Nevro's HF10 SCS therapy, which provides electrical pulses to the spinal cord at a rate up to 10 kHz to reduce the sensation of pain.  The electrical pulses are conveyed by small electrodes placed near the spinal cord and connected to a compact battery-powered generator implanted under the skin.  Data from this and other European clinical studies suggest that Nevro's HF10 SCS therapy may offer the ability to treat low back pain and other challenging conditions, including chronic pain patients who do not respond to traditional low-frequency SCS therapy.

The Senza system is presently the subject of the SENZA-RCT study, a prospective, randomized, controlled pivotal study in the United States to further evaluate the safety and efficacy of Nevro's Senza system in patients with chronic pain.  The unblinded study will enroll up to approximately 300 patients at up to 15 leading pain centers across the U.S. and will compare its performance against treatment with traditional low-frequency SCS.  In the United States, the system is limited by federal law to investigational use and is not available for promotion or sale.

About Nevro Corp.

Headquartered in Menlo Park, California, privately held Nevro Corp. is focused on the development and commercialization of high-frequency spinal cord stimulation (HF-SCS) for the treatment of chronic pain and other disorders.  The company has developed the Senza HF-SCS system, only SCS system capable of delivering stimulation of up to 10 kHz and providing HF10 SCS therapy.  The company's proprietary high-frequency waveform technology appears unique in its potential to effectively treat challenging conditions such as low back pain while enhancing patient experience.  Nevro's investors include Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, Johnson & Johnson Development Corporation, MPM Capital, and Three Arch Partners.  For more information, please visit www.nevro.com.

Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,067.56 -30.89 -0.18%
S&P 500 2,002.28 -1.09 -0.05%
NASDAQ 4,598.1880 +17.9170 0.39%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs